PETOSKEY, Mich.--(BUSINESS WIRE)--BioStar Ventures, a strategic venture capital partnership focused on accelerating value creation for medical device and connected health technologies in cardiovascular and orthopedic medicine, today announced it has raised over $68 million for BioStar III, its third and largest fund to date. BioStar I and BioStar II funds collectively totaled $65 million.
With BioStar III, BioStar Ventures will continue to execute on its strategy to invest in companies that support the development of promising medical technologies that address unmet needs. Since its inception, BioStar Ventures has invested in more than 30 seed or early-stage med-tech companies, with nearly half of those being acquired by leading medical device manufacturers.
“Our business model is to engage world-renowned practicing physicians to provide cutting-edge clinical insight and medical expertise to our team, informing investment decisions and offering enhanced value to both entrepreneurs and investors,” said Louis Cannon, M.D., Founder and Senior Managing Director, BioStar Ventures. “The support from our current and new investors, as well as our track record of successful exits, validates that our investment approach helps realize the market potential of health innovations that can improve patient care.”
BioStar III will be focused specifically on medical device innovation within the areas that BioStar Ventures’ physician medical venture partners are recognized as Key Opinion Leaders and current practitioners in cardiovascular and orthopedic intervention. BioStar III’s mission is to realize the potential of device technologies primarily in cardiovascular and orthopedic medicine, leading to innovations in patient care and strong returns for its partners.
“Deal flow is tremendous and filled with transformative opportunities,” continued Dr. Cannon. “BioStar III has five investments in the portfolio, two of which have received FDA approval and are preparing for commercialization, and we anticipate several new technologies will be added to the pipeline shortly.”
Apply for Funding
BioStar Ventures encourages entrepreneurs to apply for funding by submitting an application. For more information about the Company’s evaluation process and to apply, visit http://www.biostarventures.com/#!evaluation-process/c1z78. For more information about BioStar Ventures and its existing investments, visit its website www.biostarventures.com.
About BioStar Ventures
BioStar Ventures is a strategic venture capital partnership focused on accelerating value creation for medical device and connected health technologies in cardiovascular and orthopedic medicine. Combining the insight of seasoned venture capitalists and world-renowned medical thought leaders, BioStar Ventures identifies proprietary technologies that meet unmet patient needs, as well as the acquisition criteria of major medical device companies, and then acts as a true value-added investor, providing both capital and clinical expertise to mitigate risk, optimize product development and secure successful exit. BioStar Ventures fills an important funding gap in translational medical device development, making initial investments up to $1 million and typically from $2 to $6 million over the life of an investment. For more information, visit www.biostarventures.com.
Forwarding-Looking Statements
CERTAIN STATEMENTS IN THIS PRESS RELEASE CONSTITUTE FORWARD-LOOKING STATEMENTS. WHEN USED IN THIS PRESS RELEASE, THE WORDS “WILL,” “ANTICIPATE,” AND SIMILAR EXPRESSIONS OR THE NEGATIVES THEREOF ARE GENERALLY INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. SUCH FORWARD-LOOKING STATEMENTS, INCLUDING THE INTENDED ACTIONS AND PERFORMANCE OBJECTIVES OF FUND, ITS GENERAL PARTNER, BIOSTAR VENTURES OR ANY BIOSTAR PORTFOLIO COMPANY REFERENCED HEREIN, INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES, AND OTHER IMPORTANT FACTORS THAT COULD CAUSE THE ACTUAL RESULTS, PERFORMANCE, OR ACHIEVEMENTS OF THE GENERAL PARTNER, OR ANY BIOSTAR FUND OR PORTFOLIO COMPANY TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE, OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD-LOOKING STATEMENTS. NO REPRESENTATION OR WARRANTY IS MADE AS TO FUTURE PERFORMANCE OR SUCH FORWARD-LOOKING STATEMENTS. ALL FORWARD-LOOKING STATEMENTS IN THIS PRESS RELEASE SPEAK ONLY AS OF THE DATE HEREOF. THE FUND, ITS GENERAL PARTNER AND BIOSTAR VENTURES EXPRESSLY DISCLAIM ANY OBLIGATION OR UNDERTAKING TO DISSEMINATE ANY UPDATES OR REVISIONS TO ANY FORWARD-LOOKING STATEMENT CONTAINED HEREIN TO REFLECT ANY CHANGE IN ITS EXPECTATION WITH REGARD THERETO OR ANY CHANGE IN EVENTS, CONDITIONS, OR CIRCUMSTANCES ON WHICH ANY SUCH STATEMENT IS BASED.
